| abstract |
Diseases involving fibrosis (e.g., heart, kidney, fibrosis of the liver and lung) and scleroderma; Inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; Diseases involving eye diseases such as macular degeneration; Heterocyclic compounds that are lysophosphatidic acid receptor ligands useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions include, but are not limited to, neurological disorders such as pruritus and pain. A non-limiting example of that compound is (RS) -3-cyclopropyl-2- {4- [3-methyl-4 - ((R) -1- phenyl-ethoxycarbonylamino) (2-chloro-phenyl) -ethoxycarbonylamino] -4-fluoro-pyrazole-l- Yl} -2-fluoro-biphenyl-4-yl) -cyclopropanecarboxylic acid. |